Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022
20 Outubro 2022 - 5:05PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care
diagnostics company focused on infectious diseases, announced today
that it will release financial results for the third quarter of
2022 after the close of trading on Thursday, November 3, 2022.
The company’s management team will host a corresponding
conference call beginning at 4:30 p.m. Eastern Time on November 3,
2022. Investors interested in listening to the conference call may
do so by dialing 888-506-0062 from the US or 973-528-0011 from
outside the US and providing Entry Code: 600643 or by accessing
www.chembio.com/investors/calendar-of-events/. A replay of the call
will be available by dialing 877-481-4010 from the US or
919-882-2331 from outside the US using passcode 46584 or by
accessing www.chembio.com/investors/calendar-of-events/.
About Chembio DiagnosticsChembio is a leading
diagnostics company focused on developing and commercializing
point-of-care tests used to detect and diagnose infectious
diseases, including sexually transmitted disease, insect vector and
tropical disease, COVID-19 and other viral and bacterial
infections, enabling expedited treatment. Coupled with Chembio’s
extensive scientific expertise, its novel DPP technology offers
broad market applications beyond infectious disease. Chembio’s
products are sold globally, directly and through distributors, to
hospitals and clinics, physician offices, clinical laboratories,
public health organizations, government agencies, and consumers.
Learn more at www.chembio.com.
Investor
contact: |
Philip TaylorGilmartin Group(415) 937-5406investor@chembio.com |
Chembio Diagnostics (NASDAQ:CEMI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Chembio Diagnostics (NASDAQ:CEMI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024